DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
This quarter Dexcom raked in $405 million in revenue, compared to $280.5 million in 2019’s Q1. This represents a 44% increase year over year (YoY), and beats the company's revenue goal by $46.7 ...
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
TipRanks on MSN
DEXCOM call volume above normal and directionally bullish
Bullish option flow detected in DexCom (DXCM) with 1,753 calls trading, 1.1x expected, and implied vol increasing almost 2 points to 45.27%.
DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...
With a price-to-earnings (or "P/E") ratio of 66.4x DexCom, Inc. (NASDAQ:DXCM) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E ...
Dexcom's stock has been under a lot of selling pressure ever since Abbott won FDA approval for the FreeStyle Libre System in late 2017. The reason is that the Libre system does not need to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback